肾细胞癌中癌症相关成纤维细胞:预后与抗血管生成治疗耐药的意义
本研究基于三个独立ccRCC患者队列的组织样本,通过转录特征分析CAFs与肿瘤淋巴管生成,并与肿瘤发展和预后相关;同时在ccRCC细胞与CAFs共培养中分析CAFs对迁移和VEGFR-TKI耐药的影响。结果显示VEGFR-TKI显著增加肿瘤中CAFs数量,瘤内CAFs比例与较短的无病生存和总生存相关,CAFs促进迁移并降低VEGFR-TKI的细胞毒效应,提示CAFs是ccRCC治疗耐药的新靶点。
要点
- VEGFR-TKI显著增加ccRCC肿瘤中CAFs数量。
- 瘤内CAFs比例高与较短的无病生存和总生存相关。
- CAFs促进肿瘤细胞迁移并降低VEGFR-TKI细胞毒效应。
核心结论
- VEGFR-TKI促进ccRCC中CAFs发展,CAFs促进肿瘤侵袭性、转移播散和治疗耐药。
- CAFs可能成为克服ccRCC治疗耐药的新治疗靶点,CAF靶向与免疫治疗联合在ccRCC中具有相关性。
研究设计与样本
- 研究纳入三个独立ccRCC患者队列的组织样本,通过转录特征分析CAFs和肿瘤淋巴管生成,并与肿瘤发展和预后相关。
- 在ccRCC细胞与CAFs共培养中分析CAFs对肿瘤细胞迁移和VEGFR-TKI耐药的影响。
主要发现
- 队列结果和计算机模拟研究显示VEGFR-TKI显著增加肿瘤中CAFs数量。
- 同一ccRCC患者群体中,瘤内CAFs比例与较短的无病生存和总生存相关。
- CAFs的存在与淋巴管生成和淋巴结转移相关。
- CAFs增加肿瘤细胞迁移并降低VEGFR-TKI依赖的细胞毒效应。
临床怎么用
- 在ccRCC抗血管生成治疗中需关注CAFs介导的耐药,可考虑将CAFs作为潜在干预靶点。
- CAF靶向与免疫治疗联合策略在ccRCC中值得进一步探索。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the role of cancer-associated fibroblasts (CAFs) in clear cell renal cell carcinoma (ccRCC) with respect to tumour aggressiveness, metastasis development, and resistance to anti-angiogenic therapy (vascular endothelial growth factor receptor-tyrosine kinase inhibitors [VEGFR-TKI]). PATIENTS AND METHODS: Our study involved tissue samples from three distinct and independent cohorts of patients with ccRCC. The presence of CAFs and tumour lymphangiogenesis was investigated, respectively, by transcriptional signatures and then correlated with tumour development and prognosis. The effect of these CAFs on tumour cell migration and VEGFR-TKI resistance was analysed on co-cultures of ccRCC cells with CAFs. RESULTS: Results from our cohorts and from in silico investigations showed that VEGFR-TKI significantly increase the number of CAFs in tumours. In the same populations of patients with ccRCC, the proportion of intra-tumoral CAFs correlated to shorter disease-free and overall survival. The presence of CAFs was also correlated with lymphangiogenesis and lymph node metastasis. CAFs increased the migration and decreased the VEGFR-TKI-dependent cytotoxic effect of tumour cells. CONCLUSIONS: Our results show that VEGFR-TKI promote the development of CAFs, and CAFs favour tumour aggressiveness, metastatic dissemination, and resistance to treatment in ccRCC. CAFs could represent a new therapeutic target to fight resistance to treatment of ccRCC. Targeting CAF and immunotherapies combination are emerging as efficient treatments in many types of solid tumours. Our results highlight their relevance in ccRCC.
引用
- Ambrosetti D, Coutts M, Paoli C, et al. Cancer-associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti-angiogenic therapy. BJU Int. 2021. PMID: 34107167. doi:10.1111/bju.15506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。